Table 1.
Baseline characteristics of the patients.
| Age (years), median (IQR) | 65.0 (62.0–68.0) |
| PSA (ng/mL), median (IQR) | 15.9 (9.37–40.0) |
| Clinical stage, n (%) | |
| T1–T2 | 14 (82.35) |
| T3 | 3 (17.65) |
| Biopsy ISUP grade group, n (%) | |
| 1 | 1 (5.88) |
| 2 | 6 (35.29) |
| 3 | 2 (11.76) |
| 4 | 6 (35.29) |
| 5 | 2 (11.76) |
| Pathological stage, n (%) | |
| T2 | 1 (5.88) |
| T3a | 5 (29.41) |
| T3b | 11 (64.71) |
| Pathological ISUP grade group, n (%) | |
| 2 | 1 (5.88) |
| 3 | 4 (23.53) |
| 4 | 2 (11.76) |
| 5 | 10 (58.82) |
| Pathological lymph node metastasis, n (%) | |
| N0 | 6 (35.3) |
| N1 | 11 (64.7) |
IQR = interquartile range; PSA = prostate specific antigen; ISUP = International Society of Urological Pathology.